Synbio Tech Inc
TTPEX:129546.75
TWD
-0.30
(-0.64%)
ISIN
TW0001295004
Return %
Stock
S&P 500
1Y
-59.92
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- San Lien Yang
- Full Time Employees
- 92
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- No. 66, Beiling 6th Road Kaohsiung City KH Taiwan 821
- IPO Date
- May 27, 2025
- Website
- synbiotech.com
- Similar Companies
- Business
- Synbio Tech Inc. (1295.TWO) develops and manufactures synthetic biology-based products for the food, cosmetics, and health supplement industries. The company offers a diverse portfolio of natural ingredients and additives, including fermented L-carnitine for dietary supplements; no-added-sugar sweeteners such as Sweetgreen F and Sweetgreen P derived from monk fruit and other plant sources; plant-based preservatives like Natamisin and fermented PHA for food and beverage applications; cosmetic active ingredients including fermented glutathione, NADH, and NMN; and health-focused compounds such as astaxanthin and beta-glucan produced through proprietary microbial fermentation processes. These products target manufacturers and brands seeking clean-label, sustainable alternatives to synthetic or chemically extracted ingredients, with operations spanning Asia, North America, and Europe from its headquarters in Taipei, Taiwan, where it was founded in 2014. In geographic scope, Synbio Tech maintains production facilities in Taiwan and sales networks across key markets in Asia-Pacific, the United States, and the European Union, serving B2B customers in functional foods, personal care, and nutraceuticals. The company operates as an independent entity listed on the Taipei Exchange, emphasizing biotechnology innovation through its SynbioBeta platform for precision fermentation. Recent developments include the launch of new high-purity fermented NMN and NADH products in 2024 to capitalize on the anti-aging supplement market; a strategic partnership with a leading Japanese cosmetics firm announced in early 2025 for co-developing bio-active peptides; and expansion of production capacity via a new facility in southern Taiwan completed in late 2024 to meet rising global demand for vegan-friendly ingredients. No major acquisitions or funding rounds were reported in the last two years, though the company has pursued R&D collaborations with universities in Taiwan and the US for next-generation synbio strains.